Optimizing drug outcomes through pharmacogenetics: A case for preemptive genotyping

Clinical Pharmacology and Therapeutics

Volumn 92, Issue 2, 2012, Pages 235-242

  Schildcrout, J S ^a   Denny, J C ^a   Bowton, E ^a   Gregg, W ^a   Pulley, J M ^a   Basford, M A ^a   Cowan, J D ^a   Xu, H ^a   Ramirez, A H ^a   Crawford, D C ^b   Ritchie, M D ^c   Peterson, J F ^a,d   Masys, D R ^a   Wilke, R A ^a   Roden, D M ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c PENNSYLVANIA STATE UNIVERSITY   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ARIPIPRAZOLE; ATORVASTATIN; AZATHIOPRINE; CARVEDILOL; CELECOXIB; CLOPIDOGREL; CODEINE; COTRIMOXAZOLE; DIAZEPAM; DOXEPIN; ESOMEPRAZOLE; FLUOXETINE; METOPROLOL; PROPRANOLOL; RABEPRAZOLE; RISPERIDONE; SIMVASTATIN; TAMOXIFEN; TERBINAFINE; TIMOLOL MALEATE; TIOTROPIUM BROMIDE; TOLTERODINE; TRAMADOL; VENLAFAXINE; WARFARIN;

ADULT; AFRICAN AMERICAN; AGED; ALLELE; ARTICLE; BLEEDING; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER RECURRENCE; DRUG EXPOSURE; DRUG SAFETY; ETHNICITY; EUROPEAN AMERICAN; FEMALE; FOLLOW UP; GENE FREQUENCY; GENETIC ANALYSIS; GENOTYPE; HEART INFARCTION; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MORTALITY; MYOPATHY; OUTCOME ASSESSMENT; PHARMACOGENETICS; PRIORITY JOURNAL; SIDE EFFECT; STROKE; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; DRUG TOXICITY; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PATIENT SAFETY; PHARMACEUTICAL PREPARATIONS; PHARMACOGENETICS; POLYMORPHISM, GENETIC;

EID: 84864118842     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2012.66     Document Type: Article

References (32)

1. Weinshilboum, R.M. & Wang, L. Pharmacogenetics and pharmacogenomics: development, science, and translation. Annu. Rev. Genomics Hum. Genet. 7, 223-245 (2006). (Pubitemid 44627929)
2. Roden, D.M. & Tyndale, R.F. Pharmacogenomics at the tipping point: challenges and opportunities. Clin. Pharmacol. Ther. 89, 323-327 (2011).
3. Frueh, F.W. et al. Pharmacogenomic biomarker information in drug labels approved by the United States Food and Drug Administration: prevalence of related drug use. Pharmacotherapy 28, 992-998 (2008).
4. Lesko, L.J. & Zineh, I. DNA, drugs and chariots: on a decade of pharmacogenomics at the US FDA. Pharmacogenomics 11, 507-512 (2010).
5. Hamburg, M.A. & Collins, F.S. The path to personalized medicine. N. Engl. J. Med. 363, 301-304 (2010).
6. Meckley, L.M., Gudgeon, J.M., Anderson, J.L., Williams, M.S. & Veenstra, D.L. A policy model to evaluate the benefits, risks and costs of warfarin pharmacogenomic testing. Pharmacoeconomics 28, 61-74 (2010).
7. Patrick, A.R., Avorn, J. & Choudhry, N.K. Cost-effectiveness of genotypeguided warfarin dosing for patients with atrial fibrillation. Circ. Cardiovasc. Qual. Outcomes 2, 429-436 (2009).
8. Collins, F. Opportunities and challenges for the NIH-an interview with Francis Collins. Interview by Robert Steinbrook. N. Engl. J. Med. 361, 1321-1323 (2009).
9. Zuvich, R. et al. Balancing ethics and genetics: classifying individuals by their ancestry groups. American Society of Human Genetics Annual Meeting, Washington, DC; 2-6 November 2010.
10. S chroth, W. et al. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA 302, 1429-1436 (2009).
11. Link, E. et al.; SEARCH Collaborative Group. SLCO1B1 variants and statininduced myopathy- A genomewide study. N. Engl. J. Med. 359, 789-799 (2008).
12. Klein, T.E. et al.; International Warfarin Pharmacogenetics Consortium. Estimation of the warfarin dose with clinical and pharmacogenetic data. N. Engl. J. Med. 360, 753-764 (2009).
13. Kim, M.M. et al. Hospitalization costs associated with warfarinrelated bleeding events among older community-dwelling adults. Pharmacoepidemiol. Drug Saf. 19, 731-736 (2010).
14. Delea, T.E., Taneja, C., Sofrygin, O., Kaura, S. & Gnant, M. Cost-effectiveness of zoledronic acid plus endocrine therapy in premenopausal women with hormone-responsive early breast cancer. Clin. Breast Cancer 10, 267-274 (2010).
15. S chackman, B.R., Scott, C.A., Walensky, R.P., Losina, E., Freedberg, K.A. & Sax, P.E. The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV. AIDS 22, 2025-2033 (2008).
16. Delaney, J.T. et al. Predicting clopidogrel response using DNA samples linked to an electronic health record. Clin. Pharmacol. Ther. 91, 257-263 (2012).
17. Kho, A.N. et al. Electronic medical records for genetic research: results of the eMERGE consortium. Sci. Transl. Med. 3, 79re1 (2011).
18. S orich, M.J., Vitry, A., Ward, M.B., Horowitz, J.D. & McKinnon, R.A. Prasugrel vs. clopidogrel for cytochrome P450 2C19-genotyped subgroups: integration of the TRITON-TIMI 38 trial data. J. Thromb. Haemost. 8, 1678-1684 (2010).
19. Xu, H., Stenner, S.P., Doan, S., Johnson, K.B., Waitman, L.R. & Denny, J.C. MedEx: a medication information extraction system for clinical narratives. J. Am. Med. Inform. Assoc. 17, 19-24 (2010).
20. Peissig, P. et al. Construction of atorvastatin dose-response relationships using data from a large population-based DNA biobank. Basic Clin. Pharmacol. Toxicol. 100, 286-288 (2007). (Pubitemid 46435086)
21. T atonetti, N.P. et al. Detecting drug interactions from adverse-event reports: interaction between paroxetine and pravastatin increases blood glucose levels. Clin. Pharmacol. Ther. 90, 133-142 (2011).
22. Roden, D.M. et al. Development of a large-scale de-identified DNA biobank to enable personalized medicine. Clin. Pharmacol. Ther. 84, 362-369 (2008).
23. Dumitrescu, L. et al. Assessing the accuracy of observer-reported ancestry in a biorepository linked to electronic medical records. Genet. Med. 12, 648-650 (2010).
24. Egan A. & Colman E. Weighing the benefits of high-dose simvastatin against the risk of myopathy. N. Engl. J. Med. 365:285-287.
25. Kaplan E.L. & Meier P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 1958;53:457-481.
26. Farez-Vidal, M.E., Gandia-Pla, S., Blanco, S., Gíez-Llorente, C. & Gíez-Capilla, J.A. Multi-mutational analysis of fifteen common mutations of the glucose 6-phosphate dehydrogenase gene in the Mediterrranean population. Clin. Chim. Acta 395, 94-98 (2008).
27. Chinevere, T.D., Murray, C.K., Grant, E. Jr, Johnson, G.A., Duelm, F. & Hospenthal, D.R. Prevalence of glucose-6-phosphate dehydrogenase deficiency in U.S. Army personnel. Mil. Med. 171, 905-907 (2006). (Pubitemid 44412158)
28. S alvidio, E., Pannacciulli, I., Tizianello, A. & Ajmar, F. Nature of hemolytic crises and the fate of G6PD deficient, drug-damaged erythrocytes in Sardinians. N. Engl. J. Med. 276, 1339-1344 (1967).
29. Mallal, S. et al.; PREDICT-1 Study Team. HLA-B*5701 screening for hypersensitivity to abacavir. N. Engl. J. Med. 358, 568-579 (2008). (Pubitemid 351214284)
30. Higgs, J.E., Payne, K., Roberts, C. & Newman, W.G. Are patients with intermediate TPMT activity at increased risk of myelosuppression when taking thiopurine medications? Pharmacogenomics 11, 177-188 (2010).
31. Mega, J.L. et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA 304, 1821-1830 (2010).
32. S anderson, S., Emery, J. & Higgins, J. CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis. Genet. Med. 7, 97-104 (2005). (Pubitemid 40261834)